


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT
Attorney Docket No.: 016930-003920US
Client Ref. No.: CJ-0897Q
Customer No.: 20350

On 10/15/04

TOWNSEND and TOWNSEND and CREW LLP

By: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ATENCIO *et al.*

Application No.: 09/416,735

Filed: October 13, 1999

For: CALPAIN INHIBITORS AND
THEIR APPLICATIONS

Confirmation No. 6563

Examiner: Falk, Anne Marie

Art Unit: 1632

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Action mailed March 25, 2004 (hereinafter, "the Office Action"), Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please enter the following amendments and remarks:

Appl. No. 09/416,735
Amdt. dated October 15, 2004
Reply to Office Action of March 25, 2004

PATENT

Amendments to the Specification begin on page 3 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 6 of this paper.

Remarks/Arguments begin on page 9 of this paper.